Form 4: Tango Therapeutics Insider Trades Common Stock

Adam Crystal, President of R&D at Tango Therapeutics, executed a Rule 10b5-1 trading plan, acquiring 27,000 shares and selling 27,000 shares.

Summary

• Adam Crystal, President of R&D at Tango Therapeutics, Inc., reported transactions involving common stock on April 1, 2026.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.
• Crystal acquired 27,000 shares of common stock at a price of $5.20 per share.
• Concurrently, Crystal sold 27,000 shares of common stock at a weighted-average price of $21.2029, with individual sale prices ranging from $21.00 to $21.69.
• Following these transactions, Crystal beneficially owns 112,622 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by an executive can be a negative signal, the structured nature of the Rule 10b5-1 plan and the simultaneous acquisition suggest a planned portfolio adjustment rather than a definitive negative outlook.

Positives

• The execution of a Rule 10b5-1 trading plan indicates proactive and planned insider trading strategy, often aimed at diversifying holdings or managing personal finances without violating insider trading regulations.
• The acquisition of shares at a lower price ($5.20) suggests a potential belief in the company's future value by the reporting person.
• The sale of shares at a significantly higher price ($21.2029 average) indicates a profitable transaction for the reporting person.

Negatives

• The sale of a substantial number of shares (27,000) by a key executive could be interpreted negatively by the market, potentially signaling a lack of confidence or a need for liquidity.
• The significant difference between the acquisition price and the sale price, while profitable for the insider, highlights the volatility or significant price appreciation of the stock during the period covered by the plan.

Risks

• The sale of shares by a high-ranking executive could be perceived by the market as a negative signal, potentially impacting investor sentiment and stock price.
• The Rule 10b5-1 plan itself, while designed to prevent insider trading, can be subject to scrutiny if not properly structured or if market conditions change drastically around its execution.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It solely reports past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a Rule 10b5-1 plan by an executive like Adam Crystal at Tango Therapeutics is a common practice to manage personal stock portfolios while adhering to regulations, especially in the dynamic biotechnology sector where stock prices can be volatile.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a key executive as a potential negative signal, possibly leading to short-term stock price pressure, despite the Rule 10b5-1 plan context.
• Employees: May view the executive's stock sale with mixed feelings, depending on their own confidence in the company's future prospects.
• Management: The transaction is executed under a pre-defined plan, indicating adherence to corporate governance and regulatory requirements for insider trading.

Key Dates

Recommendation

The filing reports an insider executing a pre-planned sale of stock. While insider selling can be a negative indicator, the structured Rule 10b5-1 plan and the simultaneous acquisition suggest a planned portfolio management rather than a strong negative view on the company's future. The significant profit realized on the sale also indicates a successful prior investment. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Tango Therapeutics.

Keywords

Tango Therapeutics, TNGX, Form 4, Insider Trading, Rule 10b5-1, Stock Transaction, Beneficial Ownership, Adam Crystal, President R&D, Common Stock